In a study conducted by Abbasi et al in the Medical Research Center of Tabriz University of Medical Sciences in 2009, the effect of HESA-A on the prognosis of oral cancers was examined and it was reported that the use of oral HESA-A reduces the expression of P53 in patients as the rates of P53 were 53.4% and 13.6% in patients receiving doses of 250 and 500 mg/kg, respectively.25 This evidence concerns the gene TP53 and lip and oral cavity carcinoma.